Eidos Therapeutics (Eidos Therapeutics) EBIT : $-98.61 Mil (TTM As of Sep. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics EBIT?

Eidos Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2020 was $-29.41 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2020 was $-98.61 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eidos Therapeutics's annualized ROC % for the quarter that ended in Sep. 2020 was -1,110.49%. Eidos Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -2,327.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Eidos Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -2.13%.

Eidos Therapeutics EBIT Historical Data

The historical data trend for Eidos Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics EBIT Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

EBIT

-2.39

-11.94

-39.71

-37.51

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
EBIT	Get a 7-Day Free Trial											6.93	-18.65	-22.31	-28.25	-29.41

Competitive Comparison of Eidos Therapeutics's EBIT

For the Biotechnology subindustry, Eidos Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eidos Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's EV-to-EBIT falls into.

Eidos Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.61 Mil.

Eidos Therapeutics (NAS:EIDX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eidos Therapeutics's annualized ROC % for the quarter that ended in Sep. 2020 is calculated as:

	ROC % (Q: Sep. 2020 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2020 )	+	Invested Capital (Q: Sep. 2020 ))	/ count )
=	-117.612 * ( 1 - 0% )	/	( (9.804	+	11.378)	/ 2 )
=	-117.612	/	10.591
=	-1,110.49 %

where

	Invested Capital		(Q: Jun. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	186.67	-	13.462	-	( 174.821	-	max(0, 15.389	-	178.793	+	174.821	))
=	9.804

	Invested Capital		(Q: Sep. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	161.351	-	10.252	-	( 147.327	-	max(0, 13.827	-	153.548	+	147.327	))
=	11.378

Note: The Operating Income data used here is four times the quarterly (Sep. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Eidos Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2020 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2020		Q: Sep. 2020
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-117.64	/	( ( (5.098 + max(-10.987, 0))	+	(5.012 + max(-7.247, 0)) )	/	2 )
=	-117.64	/	( ( 5.098	+	5.012 )	/	2 )
=	-117.64	/	5.055
=	-2,327.20 %

where Working Capital is:

	Working Capital		(Q: Jun. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.818)	-	(13.462	+	0	+	1.343)
=	-10.987

	Working Capital		(Q: Sep. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	5.981)	-	(10.252	+	0	+	2.976)
=	-7.247

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eidos Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2020 )
	=	-98.614	/	4624.796
	=	-2.13 %

Eidos Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (Eidos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Executives

Uma Sinha	director, officer: Chief Scientific Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle	officer: Senior Vice President, Finance	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle	officer: Chief Business Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox	officer: See Remarks	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen	director	3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat	director, 10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu	officer: CFO and Secretary	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc.	10 percent owner	421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar	director, 10 percent owner, officer: Chief Executive Officer	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116